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Mouse Germline Restriction of Oct4
Expression by Germ Cell Nuclear Factor
vivo mutagenesis has shown that, in the absence of
Oct4, compacted morula cells do not differentiate along
the pluripotent inner cell mass lineage (Nichols et al.,
Guy Fuhrmann,1,4,6 Arthur C.-K. Chung,2,6
Kathy J. Jackson,2 Geoffrey Hummelke,2
Aria Baniahmad,3 Julien Sutter,1 Ian Sylvester,4
1998). In embryonic stem cells, an Oct4 expression levelHans R. Scho¨ler,4,5,6 and Austin J. Cooney2,6
between 50% and 150% of the endogenous amount1 Centre de Neurochimie
appears to be permissive for self-renewal and mainte-Laboratoire de Neurobiologie du De´veloppement
nance of cell potency (Niwa et al., 2000).et de la Re´ge´ne´ration
Oct4 is downregulated during gastrulation when stemFRE 2373 CNRS
cells differentiate, and eventually its expression is con-5 rue Blaise Pascal
fined to the germ cell lineage (Scho¨ler et al., 1990; Yeom67084 Strasbourg Cedex
et al., 1996). Consistent with its expression profile, Oct4France
is active in embryonic stem (ES), embryonal carcinoma2 Department of Molecular and Cellular Biology
(EC), and embryonic germ (EG) cells (Yeom et al., 1996).Baylor College of Medicine
Upon treatment with retinoic acid (RA), these embryonal1 Baylor Plaza
cells differentiate and Oct4 is rapidly downregulatedHouston, Texas 77030
(Minucci et al., 1996).3 Genetic Institute
Previously, we and others have reported the identifi-University of Giessen
cation of promoter elements important for the regulationHeinrich-Buff-Ring 58-62
of Oct4 in EC cells (Pikarsky et al., 1994; Schoorlemmer35392 Giessen
et al., 1994; Sylvester and Scho¨ler, 1994; Ben-ShushanGermany
et al., 1995). Specifically, a domain in the proximal re-4 The Center for Animal Transgenesis
gion, contains an overlapping set of regulatory ele-and Germ Cell Research
ments, comprising three direct repeats (R1, R2, and R3)Department of Animal Biology
with a spacing of either 1 or 0 bp (DR1 and DR0; FigureThe School of Veterinary Medicine
1A). Several orphan members of the nuclear receptorUniversity of Pennsylvania
gene superfamily (in particular, COUP-TFI and COUP-New Bolton Center
TFII) bind to these repeats in vitro and are considered toMyrin Building
be involved in repression of Oct4 expression. However, a382 West Street Road
precise time course analysis of Oct4 expression duringKennett Square, Pennsylvania 19248
RA-induced EC cell differentiation demonstrates that
the initial Oct4 downregulation precedes the appear-
ance of COUP-TFI and COUP-TFII (Fuhrmann et al.,Summary
1999).
The repeat sequence includes potential sites for theThe POU-domain transcription factor Oct4 is essential
binding of two other orphan nuclear receptors, steroido-for the maintenance of the mammalian germline. In
genic factor-1 (SF-1) and germ cell nuclear factorthis study, we show that the germ cell nuclear factor
(GCNF). SF-1 is specifically expressed in steroidogenic(GCNF), an orphan nuclear receptor, represses Oct4
tissues and shown to be essential only during late organ-gene activity by specifically binding within the proxi-
ogenesis, as depicted by targeted mutagenesis re-mal promoter. GCNF expression inversely correlates
sulting in adrenal and gonadal agenesis (Luo et al.,with Oct4 expression in differentiating embryonal
1995). GCNF was originally cloned from a mouse testis
cells. GCNF overexpression in embryonal cells re-
cDNA library (Chen et al., 1994). GCNF is widely ex-
presses Oct4 gene and transgene activities, and we pressed in the mouse embryo after gastrulation and
establish a link to transcriptional corepressors medi- subsequently in the developing nervous system (Su¨sens
ating repression by GCNF. In GCNF-deficient mouse et al., 1997; Chung et al., 2001). Consistent with its ex-
embryos, Oct4 expression is no longer restricted to pression pattern, targeted mutagenesis of the mouse
the germ cell lineage after gastrulation. Our studies GCNF has shown that the gene is crucial for embryonic
suggest that GCNF is critical in repressing Oct4 gene viability. GCNF-deficient embryos die around E10.5 due
activity as pluripotent stem cells differentiate and in to cardiovascular complications. In addition, they ex-
confining Oct4 expression to the germline. hibit a number of other developmental abnormalities,
including disruption of the normal anterior-posterior axis
Introduction leading to a posterior truncation, ectopic location of the
tailbud outside the yolk sac, and a halt in somitogenesis
Oct4, a member of the POU-domain family of transcrip- (Chung et al., 2001).
tion factors, plays an essential role in the maintenance GCNF binds specifically to an AGGTCA core motif
of embryonic stem cell potency and the establishment oriented as a DR0 arrangement and to certain extended
of the germ cell lineage (Pesce and Scho¨ler, 2000). In half-sites, such as TCAAGGTCA (Chen et al., 1994; Yan
et al., 1997; Cooney et al., 1998). GCNF binding sites
have been found in the promoters of many genes, includ-5 Correspondence: scholer@vet.upenn.edu
6 These authors contributed equally to this work. ing protamine 1 and 2 (Hummelke et al., 1998). GCNF
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Figure 1. The Transiently RA-Induced Factor TRIF Binds to the Oct4 Gene Promoter in Differentiating Embryonal Cells
(A) Schematic representation of the 5-flanking region of the mouse Oct4 gene. The regulatory elements in the proximal promoter (PP) are
arranged in three direct repeats (R1, R2, and R3) of the nuclear receptor half-site AGGTCA or derivatives thereof (represented by arrows). R1
and R2 are spaced by 1 base pair (DR1); R2 and R3 are not spaced (DR0). R1 partially overlaps with a SP1 binding site. The proximal enhancer
(PE) contains two RA-repressive enhancer elements (RARE).
(B) Representation of the six different R2-R3 sequences (depicted by arrows at the left or indicated in bold at the right), located within the
proximal promoter and used in the EMSA. Some of these sequences contain point mutations (whose positions are depicted by open circles
on the left or indicated by asterisks on the right).
(C) EMSA of R2-R3 DNA binding activities during RA-induced P19 cell differentiation. Radiolabeled R2R3 probe was incubated in the presence
of cell extracts treated with RA for the indicated time periods. The positions of the seven different complexes observed are indicated on the
left; C0, C2, and C4 correspond to the TRIF, COUP-TFI/TFII, and UCF complexes, respectively (indicated on the right).
(D) EMSA of the cell specificity of the R2-R3 DNA binding activities. Radiolabeled R2R3 probe was incubated in the presence of P19, F9
(either undifferentiated [UN] or differentiated [D]), 293, 3T3, or RAC65 cell extracts. The positions of the TRIF and UCF complexes are indicated
on the left.
(E) EMSA of the DNA binding characteristics of the TRIF and UCF complexes. Radiolabeled wild-type or mutated R2R3 probe (corresponding
to the sequence number and representation depicted in Figure 1B) was incubated in the presence of P19 cell extracts obtained after 18 hr
of RA treatment. The positions of the TRIF and UCF complexes are indicated on the left.
can function as a repressor of gene expression (Cooney pattern of two complexes (C0 and C4) was rapidly altered
upon RA-induced differentiation. The complex with higheret al., 1998; Yan and Jetten, 2000). In the absence of a
known ligand, GCNF’s repressive activity is likely to be mobility (C4) was prominent in extracts of undifferenti-
ated cells and rapidly downregulated after 12 hr of RAmediated, in part, by corepressors, such as the nuclear
receptor corepressor, N-CoR (Ho¨rlein et al., 1995), or treatment. The slowly migrating C0 complex appeared
by 18 hr of RA treatment and was upregulated thereafter,the silencing mediator for retinoid and thyroid hormone
receptors, SMRT (Chen and Evans, 1995). reaching a peak activity at 24–36 hr, whereupon its levels
decreased. The proteins involved in these two com-In this report, we show that the GCNF expression
pattern, both in P19 EC cells and during mouse em- plexes, C4 and C0, were termed UCF (for undifferenti-
ated cellular factor) and TRIF (transiently RA-inducedbryogenesis, inversely correlates with that of Oct4. We
also show that GCNF-dependent repression of Oct4 factor), respectively. We have recently determined that
TRIF inversely correlates with Oct4 downregulation upongene expression is driven by a DR0 arrangement located
within the Oct4 promoter. The repression function can RA-induced differentiation (Fuhrmann et al., 1999). A com-
plex of intermediate mobility (C2) appeared only 24 hrbe mediated through interactions with both of the core-
pressors N-CoR and SMRT. We further show that GCNF after RA treatment, corresponding to the previously de-
scribed COUP-TFI/TFII complex (Sylvester and Scho¨ler,is involved in repression of Oct4 gene activity during
gastrulation and, as a consequence, in the restriction 1994).
We further investigated the expression patterns ofof Oct4 expression to the germline.
UCF and TRIF in different cell lines. The fast migrating
UCF complex was only expressed in Oct4-expressingResults
cell lines, i.e., P19, F9, and RAC65 EC cells (Figure 1D).
The slowly migrating TRIF complex was only found inEarly Appearance of a Transiently Induced DNA
Binding Factor Correlates with Repression extracts of embryonal cell lines upon RA-induced differ-
entiation. The binding properties of UCF and TRIF wereof Oct4 Expression
In electrophoretic mobility shift assays (EMSAs), several characterized using various mutant versions of the R2-
R3 element (Figures 1B and 1E). Both UCF and TRIFcomplexes were shown to interact with the R2-R3 repeat
in undifferentiated P19 cells (Figure 1C). The expression required the R3 sequence for binding, although a weak
Repression of Oct4 Gene Activity by GCNF
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Figure 2. GCNF and SF-1 Are Components of the TRIF and UCF Complexes, Respectively
(A) Antibody supershift EMSA of R2-R3 DNA binding activities. Radiolabeled R2R3 probe was incubated in the presence of P19 cell extracts
obtained after 18 hr of RA treatment. The positions of the UCF and TRIF complexes are indicated on the left. These complexes only supershift
in the presence of antibodies directed against SF-1 and GCNF, respectively (marked by an asterisk); antibodies directed against RAR, RAR,
RAR, RXR, RXR, RXR, N-CoR, or SMRT (Santa Cruz) have no effect.
(B) EMSA of the DNA binding characteristics of recombinant GCNF. Radiolabeled probe (see legend to Figure 1E) was incubated in the
presence of in vitro translated GCNF. The arrow marks the specific GCNF binding activity; the supershift observed in the presence of antibodies
directed against GCNF (GCNF) is marked by an asterisk.
TRIF band was still detectable following mutation of the 1B). The DNA binding specificity of SF-1 for DR0-like
sequences has been previously described (Tsukiyamalast two nucleotides from TA to GT (Figure 1E, lanes 4
and Niwa, 1992) and correlates with the binding proper-and 5). TRIF required an intact R2 sequence, whereas
ties of UCF (Figure 1E).UCF binding was unaffected when the first three nucleo-
The DNA binding properties of GCNF are shown intides were changed from AGG to AAC (lanes 1 and 2).
Figure 2B. In vitro translated GCNF bound to R2-R3Therefore, UCF and TRIF exhibit slightly different bind-
and sequences therein, such as AGGTCAAGGCTA oring preferences within the R2-R3 repeat, namely UCF
AGGTCAAGGCTA (binding sequences are bolded; oli-to AGGTCAAGGCTA and TRIF to AGGTCAAGGCTA
gonucleotides 1, 2, and 5). The common core AGGT(crucial sequences are bolded; mutated sequences that
CAAGGCTA was crucial (oligonucleotides 3 and 4) butaffect but do not abolish binding are underlined).
not sufficient for binding, as noted by a double mutant
version not bound by GCNF (oligonucleotide 6). In the
GCNF Is a Component of TRIF, while SF-1
case of GCNF binding, a mutation in the 5-triplet outside
Is a Component of UCF the core was compensated by an intact 3-triplet, and
To identify the proteins involved in the UCF and TRIF vice versa. The DNA binding specificity of GCNF for
complexes, we performed EMSA experiments using an- extended half-sites was, thus, different from that of the
tibodies specific for different members of the nuclear TRIF complex, which was not able to bind to just the
receptor gene superfamily (Figure 2A). Antibodies raised TCAAGGCTA extended half-site (oligonucleotide 2; Fig-
against SF-1 specifically interacted with UCF, whereas ure 1E).
antibodies raised against GCNF specifically interacted The large difference in the mobilities and DNA binding
with TRIF. Other antibodies directed against the three specificities between GCNF and TRIF suggests that
retinoic acid receptors (RAR), the three retinoid X recep- there is an additional factor(s) that together with GCNF
tors (RXR), and N-CoR or SMRT did not abolish binding forms TRIF (Figure 3A). Reconstitution experiments
of any of the R2-R3 binding proteins. Antibodies raised were performed in order to determine whether GCNF is
against the histone deacetylases, HDAC1 and HDAC2, the limiting factor in the formation of the TRIF complex.
were also inefficient (data not shown). To further charac- TRIF complex formation in undifferentiated P19 cell ex-
terize the components of UCF and TRIF, mutant versions tracts is concentration dependent, as noted by in-
of the R2-R3 oligonucleotide were used in EMSAs to creased and limited TRIF formation upon increasing
determine the DNA binding specificities of UCF and amounts of in vitro-translated GCNF (Figure 3A, com-
pare lanes 3, 4, and 5). This result indicates that theTRIF, in comparison to those of SF-1 and GCNF (Figure
Developmental Cell
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Figure 3. GCNF’s Partner Protein Involved in
the TRIF Complex Is RA Inducible
(A) EMSA of in vitro reconstitution of the TRIF
complex. Radiolabeled R2R3 probe was in-
cubated in the presence of undifferentiated
P19 cells extracts (P19 UN) and increasing
amounts of in vitro translated GCNF (GCNF).
The positions of the UCF and TRIF complexes
are indicated. The arrow marks the specific
GCNF binding activity. The supershift ob-
served in the presence of antibodies directed
against GCNF (GCNF) is marked by an as-
terisk.
(B) In vitro reconstitution of the TRIF complex
during RA-induced differentiation of P19 EC
cells. Radiolabeled R2R3 probe was incu-
bated with P19 (treated with RA for the indi-
cated time periods) or 3T3 cell extracts, in
the presence or absence of in vitro translated
GCNF (GCNF [closed bar] versus control [hatched bar]). After an EMSA, the densitometric quantification of the different TRIF signals was
carried out. The bar graphs are presented as means  standard deviations and represent at least four independent measurements. Significant
differences (GCNF versus control) were determined by the Student-Fisher t test (*p  0.05; ***p  0.001).
other component(s) of the TRIF complex is expressed was downregulated. Labeling with GCNF antibodies ob-
served by immunocytochemistry (Figure 4A) showedat low levels in undifferentiated P19 cells. Strikingly,
UCF/SF-1 binding decreased after addition of GCNF to that, after 48 hr of RA treatment, the levels of the two
proteins decreased significantly. The expression patternthe extracts, although SF-1 is not a component of TRIF
(compare lanes 2 and 3). TRIF levels increased when of GCNF protein was similar to that observed at the
mRNA level (Figure 4C). Taken together, these resultsthe same amount of GCNF was added to extracts from
P19 cells treated with RA for increasing time periods demonstrate that during RA-induced differentiation of
EC cells, GCNF expression profile, both at the protein(Figure 3B). In contrast, the addition of GCNF to extracts
of differentiated cells (e.g., 3T3, COS), or the addition and RNA levels, inversely correlates with that of Oct4
and SF-1 and directly correlates with that of TRIF.of other proteins (e.g., RAR, RXR) to P19 cell extracts,
failed to reconstitute the TRIF complex (Figure 3B; data The inverse correlation of expression suggests that
downregulation of Oct4 expression could be a directnot shown).
These reconstitution experiments indicate that the consequence of GCNF upregulation during EC cell dif-
ferentiation. Therefore, we next examined the effects ofother protein(s), which forms the TRIF complex with
GCNF, is expressed in embryonal cells. Its expression GCNF overexpression on Oct4 expression in P19 cells
by using Northern blot analyses. In the presence of highor integration into the TRIF complex appears to increase
at least up to 36 hr after RA-induced differentiation and levels of transfected pCMV4-GCNF plasmid, expression
of the endogenous Oct4 gene was significantly down-then it drops.
regulated to levels similar to those observed with RA
treatment for 48 hr (Figure 4D). In contrast, Oct4 expres-
GCNF Expression Levels Inversely Correlate sion was not downregulated when P19 cells were trans-
with Those of SF-1 and Oct4 in P19 EC Cells fected with a pCMV4-GCNF-VP16 vector; GCNF-VP16
Oct4 expression is rapidly downregulated in EC cells is a fusion protein containing the transactivation domain
upon RA-induced differentiation. In light of the above of VP16 fused to GCNF and functions as a constitutive
results, two putative candidates involved in the down- transactivator (Cooney et al., 1998). These results imply
regulation of Oct4 expression are SF-1 (forming the UCF that GCNF can successfully suppress Oct4 expression
complex) and GCNF (as a component of the TRIF com- in vivo. The constitutively transcriptionally active form
plex). We, therefore, studied the GCNF and SF-1 expres- of GCNF (GCNF-VP16) is, however, able to derepress
sion patterns during RA-induced EC cell differentiation. Oct4 expression in P19 cells. These results argue for a
SF-1 protein and transcript levels decreased rapidly direct link between GCNF expression and Oct4 down-
within 24 hr of RA treatment, as observed by immunocy- regulation observed upon RA-induced differentiation of
tochemistry (Figure 4A), Western blotting (Figure 4B), embryonal cells. Moreover, all these reciprocal expres-
and RT-PCR (Figure 4C). The expression patterns of sion results strongly suggest that GCNF is a repressor
SF-1, at both the protein and transcript levels, correlated of Oct4 gene expression in vivo.
with those of Oct4 (Figures 4A–4C). Western blot analy-
sis using antibodies directed against GCNF detected
two bands of 55 and 70 kDa (Figure 4B). The expression GCNF Is a Repressor of Oct4 Gene Expression
Three lines of evidence, namely, the specific binding ofpattern of the 55 kDa protein, which corresponds to the
cloned GCNF, correlated with that of the TRIF complex, GCNF to the Oct4 promoter in vitro, the inverse correla-
tion of GCNF and Oct4 levels in differentiating P19 cells,with peak expression between 24–36 hr, as detected by
EMSA (Figure 1C). Upon RA treatment, GCNF was rap- and the effect of exogenous GCNF on the endogenous
Oct4 gene, all point to the conclusion that GCNF is aidly upregulated, in contrast to the 70 kDa protein, which
Repression of Oct4 Gene Activity by GCNF
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Figure 4. GCNF Expression Pattern Inversely Correlates with Those of SF-1 and Oct4 During RA-Induced Differentiation of P19 EC Cells
(A) Immunocytochemical analysis of GCNF, SF-1, and Oct4 expression. Fixed P19 cells, previously treated with RA for the indicated time
periods, were labeled with either anti-GCNF, anti-SF1, or anti-Oct4 primary antibody and stained with the secondary antibody Cy3. Cell nuclei
were stained with DAPI.
(B) Western blot analysis of GCNF, SF-1, and Oct4 expression. Blots of protein extracts (20 g) from P19 cells, treated with RA for the indicated
time periods, were incubated with antibodies directed against GCNF, SF-1, or Oct4. The different antibodies recognize either the 55 kDa
GCNF, the 53 kDa SF-1 or the 44 kDa Oct4 proteins (indicated by a dash on the left). Molecular masses of reference proteins are marked on
the right.
(C) RT-PCR analysis of GCNF, SF-1, and Oct4 expression. Reverse-transcripts (of 0.1 g of total RNA) prepared from P19, F9, or RAC65 cells,
treated with RA for the indicated time periods, were assayed for PCR amplification of GCNF, SF-1, Oct4, or -actin products (indicated by a
dash on the left). Molecular masses of reference DNA are marked on the right.
(D) Northern blot analysis of Oct4 expression in P19 EC cells. Upper and middle panels are autoradiographs of the same Northern blot probed
for the presence of the 1.5 kb Oct4 and GAPDH transcripts, respectively (indicated by a dash). Lanes 1–3, total RNA (25g) from undifferentiated
cells. Lane 4, total RNA (25 g) from differentiated cells treated with RA. Lanes 1 and 4, cells transfected with the pCMV4 empty vector. Lanes
2 and 3, cells transfected with the pCMV4-GCNF and pCMV4-GCNF-VP16 expression plasmid. Lower panel shows densitometry results of
Oct4 expression normalized to GAPDH expression, as per the Northern blot.
repressor of Oct4 gene expression. The transcriptional whether this repression interferes with activation of the
proximal enhancer. A genomic fragment was chosenproperties of GCNF on Oct4 expression were character-
ized in cotransfection experiments. Transfection of a Gal4- that in transgenic animals is sufficient to reproduce the
proper expression and downregulation of endogenousGCNF expression vector (Gal4 DNA binding domain
fused to the GCNF ligand binding domain) into CV-1 Oct4 in the gastrulating embryo (Yeom et al., 1996). To
directly address the role of TRIF/GCNF in Oct4 promotercells significantly repressed basal promoter activity of
the UAS tk-linked CAT (upstream-activating-sequence/ regulation, the R2 and R3 repeats were mutated and
cloned with or without the proximal enhancer in front ofthymidine kinase promoter/chloramphenicol acetyl-
transferase) reporter gene, to a level observed with Gal4- the luciferase reporter gene (Figure 5B). Upon transfec-
tion into P19 cells, all constructs lacking the proximalthyroid hormone receptor (Gal4-TR) only in the absence
of its ligand T3 (Figure 5A). This result confirms that enhancer exhibited lower promoter activity (Figure 5C),
regardless of whether they were wild-type (compare 1GCNF is indeed an intrinsic repressor of transcription
and that this function is localized to its ligand binding versus 4), contained R2 (compare 2 versus 5), or R3
mutation (compare 3 versus 6). In the presence of thedomain (LBD).
The proximal enhancer element contributes to Oct4 proximal enhancer region, the R2 mutant construct
showed significantly higher activity than the wild-typeexpression in cells derived from the epiblast, such as
P19 EC cells (Okazawa et al., 1991; Yeom et al., 1996). reporter. These results confirm that the Oct4 proximal
enhancer indeed directs an activation function in P19We assessed whether the R2-R3 repeat directs an en-
dogenous repressive activity to the Oct4 promoter and cells. Moreover, they indicate that, in these cells, an
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Figure 5. GCNF Is a Repressor of Oct4 Gene Expression in P19 EC Cells
(A) Analysis of the transrepressive properties of GCNF. Cells were cotransfected with either the Gal4, Gal4-GCNF, or Gal4-TR expression
plasmid (in the presence or absence of the ligand T3 at 107 M) and the UAS tk-linked CAT reporter plasmid. CAT activity is expressed as
cpm for 100 g of total protein.
(B) Schematic representation of the six different wild-type and mutated pOct4 reporter constructs used in transfection experiments. The direct
repeats R1, R2, and R3 are depicted by arrows and the point mutations by open circles. PE, proximal enhancer; PP, proximal promoter; LUC,
luciferase reporter gene.
(C) Analysis of the endogenous activity of wild-type and mutant Oct4 promoters in P19 EC cells. Cells were transfected with one of the Oct4
reporters (corresponding to the number of the pOct-Luc construct depicted in Figure 5B). All luciferase (LUC) activities (normalized and
expressed in RLU) are presented in bar graph form as means  standard deviations and represent three independent measurements repeated
at least three times.
(D) Analysis of response element-dependent interaction between GCNF and the Oct4 promoter. Cells were cotransfected with either the empty
pCMV4 (hatched bar) or pCMV4-GCNF-VP16 (closed bar) expression plasmid and one of the Oct4 reporters (corresponding to the number of
the pOct-Luc construct depicted in Figure 5B). Luciferase activity is expressed after normalization as fold induction relative to the corresponding
pCMV4 control, which was set at 1. Results are presented in bar graph form as means  standard deviations and represent three independent
measurements repeated at least three times.
(E) Analysis of the repression properties of GCNF in P19 EC cells. Cells were cotransfected with increasing amounts of pCMV4-GCNF expression
plasmid and two different Oct4 reporters (corresponding to the pOct-Luc construct number 1 [closed square] or 2 [open square] depicted in
Figure 5B). All luciferase activities are normalized and expressed in RLU per micrograms of protein.
endogenous repressive effect is acting through the R2 GCNF repressed Oct4 reporter activity in a dose-depen-
dent manner, whereas the R2 mutation prevented re-sequence and, finally, that efficient repression depends
on the presence of the proximal enhancer. pression by GCNF (Figure 5E). Thus, mutation of the R2
sequence not only eliminates TRIF complex formationTo determine whether GCNF can regulate Oct4 pro-
moter activity in a response element-dependent man- (Figure 1E) but also abrogates repression of the Oct4
promoter by GCNF. This result shows that the R2-R3ner, we tested the effect of the pCMV4_GCNF-VP16
expression vector on six Oct4 reporter plasmids (Figure repeat in the Oct4 promoter probably mediates repres-
sion by the GCNF-composed complex TRIF in P19 cells.5B) in P19 cells. Transactivation of the reporter by the
chimera occurred only in the presence of an intact R2-
R3 repeat, whereas mutation of either half-site abolished GCNF Interacts with the Corepressors SMRT
transactivation (Figure 5D). These results indicate that, and N-CoR
in vivo, GCNF efficiently interacts only with an intact R2- In the absence of a known ligand, it seems likely that
R3, while, in vitro, it can also bind to modified R2-R3 GCNF-mediated repression requires cofactors to si-
(Figure 2B). These results also show that GCNF’s DNA lence the activity of the Oct4 promoter. In embryonal
binding domain (DBD) can directly interact with the Oct4 cells, an unknown cofactor(s) interacts with GCNF to
promoter in P19 cells to stimulate reporter gene ex- form the TRIF repressor complex. We analyzed whether
pression. GCNF repressive function could be mediated through
To determine whether GCNF represses Oct4 promoter interactions with known nuclear receptor corepressors,
activity through a direct interaction, GCNF was cotrans- such as SMRT and N-CoR. By using the yeast two-
fected with either the wild-type or the R2 mutant Oct4 hybrid assay, we observed that the DBD of LexA fused
to the LBD of GCNF (Lex DBD-GCNF LBD) stronglyreporter into P19 cells (Figure 5B, constructs 1 and 2).
Repression of Oct4 Gene Activity by GCNF
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Figure 6. GCNF Interacts with the Corepres-
sors SMRT and N-CoR
(A) Analysis of the interaction between GCNF
and SMRT or N-CoR in the yeast two-hybrid
assay. The B42 AD domain either alone (lane
1), fused to SMRT (lanes 2 and 3) or N-CoR
(lane 4) was tested for interaction with the
fusion protein LexA DBD-GCNF in the EGY
yeast strain. -galactosidase (-GAL) activity
is expressed in Miller units. AD, activation
domain; DBD, DNA binding domain; F.L., full
length; I.D., interaction domain.
(B) Analysis of the interaction between GCNF
and SMRT or N-CoR in the mammalian two-
hybrid assay. The VP16 AD domain either
alone (lane 1), fused to SMRT (lane 2), or N-CoR (lane 3) was tested for interaction with the fusion protein Gal4 DBD-GCNF in CV-1 cells. All
luciferase (LUC) activities (expressed in RLU) are presented in bar graph form as means standard deviations and represent three independent
measurements. AD, activation domain; DBD, DNA binding domain; F.L., full length; I.D., interaction domain.
(C) Analysis of the interaction between GCNF and SMRT or N-CoR in the in vitro GST pull-down assay. Radiolabeled SMRT or N-CoR was
tested for its ability to bind to either GST-GCNF fusion protein (lane 3) or GST protein alone (lane 2) immobilized on glutathione-sepharose
beads. The input lane (lane 1) contains 10% of the starting radiolabeled protein used for the interaction test. The position of each protein is
indicated on the right.
interacted with the activation domain (AD) of B42 fused detected at weak levels in the whole embryo at E6.5
(Figure 7A, upper row). At the headfold stage with sixwith either SMRT (B42 AD-SMRT) or N-CoR (B42 AD-
NCoR); this interaction activity was detected either with somites, increasing levels of GCNF mRNA were ob-
served in the neural folds and posterior of the embryo,a full-length (F.L.) or truncated form (restricted to the
interaction domain [I.D.]) of SMRT or N-CoR (Figure 6A, in contrast to decreasing levels of Oct4 mRNA (E7.5).
These results show that the GCNF expression patternlanes 2, 3, and 4). Other known corepressors like Alien
(Dressel et al., 1999) did not interact with GCNF in the is temporally and spatially different from that of Oct4.
We then analyzed the Oct4 expression pattern in GCNF-yeast two-hybrid assay (data not shown). We then asked
whether the two corepressors, SMRT and N-CoR, also deficient mouse embryos generated by homologous re-
combination (Chung et al., 2001). In the absence ofinteract with GCNF in mammalian cells (Figure 6B). A
strong interaction activity was detected between the GCNF, the Oct4 expression pattern was dramatically
altered in the headfold stage embryo with six somitesfusion proteins Gal-4 DBD-GCNF LBD and VP16 AD-
SMRT F.L. or VP16 AD-NCoR I.D. (Figure 6B, lanes 2 (Figure 7A, lower row). Whereas in wild-type embryos,
Oct4 expression was restricted from E8.0 onward toand 3, respectively). These results suggest that SMRT
and N-CoR can interact with GCNF in mammalian cells. primordial germ cells, in mutant embryos, additional
Oct4 expression domains were detected in the putativeGCNF functionality is likely due to a direct interaction,
as indicated by in vitro protein-protein pull-down assays hindbrain region and posterior of the GCNF knockout
embryos. In mutant embryos, Oct4 expression was simi-(Figure 6C). Both SMRT and N-CoR interact with a gluta-
thione-S-transferase (GST)-GCNF fusion protein. Con- lar to normal GCNF expression (compare top right and
top bottom panels in Figure 7A). In addition to these twoclusively, the two-hybrid and the GST pull-down assays
indicate that GCNF specifically interacts with corepres- Oct4 expression domains, another domain was found in
the anterior tip of the mutant mouse brain at E8.75 (Fig-sors like N-CoR and SMRT and that GCNF repression
function is likely to be mediated by a direct interaction ure 7B). These results suggest that loss of GCNF func-
tion leads to loss of repression of Oct4 expression inwith such cofactors.
somatic cells. This confirms that the functional link be-
tween GCNF and Oct4, based on our biochemical data,GCNF Restricts Oct4 Gene Expression
does indeed exist in the developing embryo.to the Germ Cell Lineage
As shown above, GCNF acts as a repressor of Oct4
gene and transgene expression in differentiating P19 Discussion
cells. Since P19 EC cells have many features in common
with mouse epiblast cells, we tested whether GCNF also Stem cell lines derived from the inner cell mass and
epiblast of the mouse embryo express Oct4 only in theacts as a repressor in the gastrulating embryo. First, we
compared GCNF and Oct4 expression patterns by whole undifferentiated state. Differentiation, initiated by an em-
bryonic cell trigger, results in Oct4 downregulation. Thismount in situ hybridization during and after embryo im-
plantation. Oct4 expression was detected in the epiblast provides a model for the early events linked to somatic
differentiation in the developing embryo (Pesce andat E6.5–7.5 (Figure 7A, middle row) and rapidly downreg-
ulated from the anterior to the posterior during gastrula- Scho¨ler, 2000). In order to elucidate the molecular mech-
anisms that control Oct4 gene expression during RA-tion, as previously described (Figure 7A and data not
shown; Scho¨ler et al., 1990; Yeom et al., 1996). By E8.5– induced differentiation of ES/EC cells and gastrulation,
we have examined the manner in which the Oct4 pro-E8.75, Oct4 expression was restricted to primordial
germ cells in the posterior of the embryo at the base of moter is regulated. In this report, we demonstrate that
the nuclear receptor GCNF is a key regulator of Oct4allantois (Figure 7A, arrowhead). GCNF expression was
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Figure 7. GCNF Is a Repressor of Oct4 Gene
Expression during Mouse Postimplantation
Development
(A) Whole-mount in situ hybridization of
GCNF and Oct4 in GCNF	/	 and GCNF/
embryos at E6.5, E7.5, and E8.5. In situ hy-
bridization with a digoxygenin-labeled ribo-
probe for GCNF or Oct4 (indicated on the right
by GCNF or OCT-4) was performed on whole
mounted wild-type or GCNF null embryos (in-
dicated on the left by GCNF 	/	 or GCNF
/). The arrowhead points to presumptive
primordial germ cells which express Oct4.
(B) Whole-mount in situ hybridization of Oct4
in GCNF/ embryos at E8.25 and E8.75. (B)
was stained three times longer than (A) to
identify weaker Oct4 expression in GCNF/




38 for E6.5, E7.5, and E8.5, respec-
tively; magnifications in (B) are 
38.
gene expression during embryonic stem cell differentia- cells (Figures 4A–4C) suggests that SF-1 may play a
positive regulatory role in Oct4 gene expression. Consis-tion and gastrulation. We show that GCNF is part of a
complex that mediates the initial repression of Oct4 tent with this hypothesis, it has recently been shown
that SF-1 and RAR form a complex with which theyexpression in RA-induced differentiation of EC cells. We
further demonstrate that GCNF-deficient embryos fail synergistically activate the Oct4 promoter (Barnea and
Bergman, 2000). However, the SF-1 knockout bypassedto restrict Oct4 expression to the germline, as evidenced
by Oct4 expression being maintained in somatic cells. the postimplantation embryonic lethality displayed by
the Oct4 knockout, suggesting that SF-1 either does notSince GCNF controls the quantitative expression of
Oct4, we surmise that GCNF constitutes a critical regula- play a significant role in regulating Oct4 expression or
its loss is compensated by other nuclear receptors.tory component of epiblast pluripotency.
Characterization of the mechanism of Oct4 gene re- GCNF is also known to bind to the DR0 response
element (Chen et al., 1994; Yan et al., 1997; Cooney etpression led to the identification of a transiently RA-
induced factor (TRIF), which binds to the R2-R3 repeat al., 1998). GCNF expression is upregulated following RA-
induced differentiation of P19 cells, with concomitantwithin the proximal promoter of the Oct4 gene (Figures
1A and 1C). The expression pattern of this novel factor downregulation of Oct4 expression (Figures 4A–4C).
Overexpressed GCNF induces a downregulation of Oct4during RA-induced differentiation of EC cells (Figure 1D)
shows a peak at 24–36 hr, suggesting that it could be expression in P19 cells (Figure 4D). Moreover, GCNF
can constitutively repress basal promoter activity wheninvolved in the initial Oct4 downregulation detected in
this time frame. Interestingly, the appearance of this fused to the heterologous Gal4 DBD (Figure 5A). When
GCNF is fused to the activation domain of the viral pro-factor is concomitant with the disappearance of another
DNA binding factor (UCF), which also binds to the R2- tein VP16, it constitutively activates the Oct4 promoter
(Figure 5D). All these results suggest that GCNF repre-R3 element and which we have identified as SF-1 (Figure
2A). The fact that SF-1 and Oct4 show the same expres- sents a negative regulator of Oct4 promoter activity.
GCNF is a component of the potential transrepressorsion profile during RA-induced differentiation in P19
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complex TRIF, as the latter is specifically supershifted with the corepressors N-CoR or SMRT and repress basal
by antibodies raised against GCNF (Figure 2A). The TRIF transcription (Chen and Evans, 1995; Ho¨rlein et al.,
complex is similar to a slowly migrating GCNF complex 1995). In the absence of a ligand, GCNF may share a
observed previously (Heinzer et al., 1998). TRIF and common cofactor, which could be N-CoR or SMRT, with
GCNF display slightly different binding specificities other nuclear receptors bound to the proximal enhancer.
(compare Figure 1E and Figure 2B) and electrophoretic We have observed that GCNF interacts with the receptor
mobility (Figure 3A), suggesting that TRIF comprises of interacting domains of both these corepressors (Figures
a heterodimer of GCNF and another factor. Until now, 6A–6C). This result is in contrast with a recent work that
it was thought that GCNF bound DNA as a homodimer showed that GCNF only interacts with N-CoR but not
(Cooney et al., 1998). Thus, the GCNF heterodimer part- with SMRT in the yeast two-hybrid assay (Yan and Jet-
ner forming TRIF may represent another known nuclear ten, 2000). The difference between these two studies
receptor or a novel embryonic nuclear receptor. This presumably arises from a different configuration of the
TRIF component allows both endogenous and overex- yeast two-hybrid assay, which may have led to steric
pressed GCNF to repress Oct4 promoter activity (Fig- hindrance. Although GCNF transcriptional repression of
ures 5C and 5E). This repression is dose dependent Oct4 promoter activity could be mediated by N-CoR and
(Figure 5E) and bears sequence-specific properties, as SMRT, these proteins do not seem to be involved in
evidenced by a mutation of the first half-site of the first the TRIF complex, since antibodies raised against them
AGGTCA core motif (Figure 5B) completely abolishing cannot supershift TRIF (Figure 2A). The slow rate of elec-
GCNF repression activity (Figures 5C and 5E). TRIF ex- trophoresis of the TRIF complex suggests that it is a
pression kinetics reflect those of GCNF following RA large complex, which may involve several factors, in-
treatment of P19 cells (Figures 1C and 4A–4C). One can cluding additional corepressors. These studies present
argue that GCNF is the limiting component of TRIF, the an emerging picture of repression of Oct4 expression as
partner protein being constitutively expressed in both one involving several factors and multiple mechanisms,
undifferentiated and differentiated cells. However, the acting in concert to bring about Oct-4 downregulation
combination of in vitro translated GCNF and extracts in embryonic cells, thus precluding its expression in
from P19 EC cells, taken at different time points of RA- somatic cells. With the onset of differentiation, activa-
induced differentiation, does not permit TRIF to reach tors of Oct4 expression, such as SF-1, are downregu-
its maximum level of expression (Figures 3A and 3B). lated. Concomitantly, an upregulation of repressors, such
This result demonstrates that GCNF’s partner protein in as GCNF/TRIF, shifts the balance of regulation from
EC cells is also RA inducible. activation to repression. Other orphan receptors, such
It has been shown that the epiblast-specific expres- as COUP-TFI and COUP-TFII, which are induced by RA
sion pattern of the Oct4 gene is driven by the proximal later on in time, may maintain GCNF-initiated repression.
enhancer, located within the 1222 bp upstream of the They may also cause an alternative level of repression,
transcriptional start site (Yeom et al., 1996). This region which would explain why Oct4 is still repressed in the
contains at least two domains (termed 1A and 1B; Figure area between the unrepressed expression domains in
1A) that act in a cooperative fashion and are recognized GCNF-deficient embryos (see Figure 7B).
by, as of yet, unknown but distinct factors (Okazawa While Oct4 expression is turned off during gastrula-
et al., 1991). The activity of the proximal enhancer is tion, GCNF expression is turned on (Figure 7A; Yeom et
restricted to epiblast-derived cells, like EC cells, and is al., 1996). This result is in agreement with a previous
necessary for the modulation of promoter activity in report, which shows relatively high GCNF transcript lev-
P19 cells prior to RA treatment and during RA-mediated els in the early postgastrulation period (Su¨sens et al.,
repression (Okazawa et al., 1991). It can, therefore, be 1997). Inverse correlation of the GCNF and Oct4 expres-
assumed that proximal enhancer activity may possibly sion profiles during gastrulation suggests that GCNF
interfere with the negative regulatory elements within
also represses Oct4 expression in vivo. Consistent with
the Oct4 promoter. Deletion of the proximal enhancer
this hypothesis, targeted gene inactivation of GCNF
causes a significant drop in the Oct4 reporter activity
leads to strong disturbances in Oct4 repression in post-(Figure 5C). Mutation of the R2 half-site disrupts the
gastrulation embryos (Figure 7B), suggesting that GCNFTRIF/GCNF binding site and abolishes the endogenous
plays an essential role in the regulation of Oct4 expres-repressive activity in P19 cells, allowing full enhancer
sion during embryonic development. In the GCNF/activation (Figure 5C). However, mutation of the R3 half-
embryos, expression of the Oct4 gene is no longer re-site does not increase the Oct4 reporter activity. The
pressed in certain differentiating somatic cells, like thereason for this difference is presently unclear; the R3
anterior neuroepithelium of the head-fold or the preso-mutation probably prevents activity of another regulator.
matic mesoderm in the posterior at E8.5–E8.75 (FigureIt is possible that this latter factor is SF-1, since it can
7). GCNF gene inactivation leads to embryonic lethalitybind to the R2 but not to the R3 half-site (Figure 1E).
around E10.5 due to multiple developmental defects,Although our studies indicate a relationship between
which can be detected as early as the 13-somite stagethe proximal enhancer and the TRIF binding site of the
(Chung et al., 2001). Unrepressed expression of Oct4 is,proximal promoter, the nature of this interaction remains
therefore, one of the earliest molecular defects observedunclear. This interaction may be mediated either directly
to date in GCNF null embryos.or indirectly through shared cofactors. One potential
The generation of GCNF-deficient embryos can becommon cofactor may be GCNF’s yet unknown partner
seen as both a GCNF loss-of-function mutation and anprotein, which is expected to bind to the first half-site
Oct4 gain-of-function mutation. The cumulative effectof the first AGGTCA core motif. In the absence of their
ligands, nuclear receptors, like TR or RAR, can interact of both, as well as the effects of unknown factors that
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129Sv genetic background) on 6.5–8.75 days postcoitum of timedare indirectly affected, very likely leads to failure of em-
pregnancies. The embryo yolk sacs were removed for genotypingbryonic development past the 13-somite stage, as pre-
(Chung et al., 2001). Whole-mount in situ hybridization was per-viously reported. Some of the developmental defects of
formed as previously described (Chung et al., 2001). The cRNA
GCNF-deficient embryos, such as posterior truncation, probes used were as described (for GCNF, see Chung et al., 2001;
may arise as a result of loss of Oct4 repression. How- for Oct4, see Scho¨ler et al., 1990).
ever, some normal development and differentiation in
areas that maintain Oct4 gene activity still occurs, as Transient Transfection Assays
indicated by the expression of brachyury T, HNF3, The Gal4-GCNF expression vector (pABgal-GCNF) was constructed
by inserting a 1.9 kb EcoRV-BamHI cDNA fragment containing theWnt3a, and Hoxb13 in the presomitic mesoderm. This
GCNF LBD and hinge region into the SmaI-BamHI sites of the pAB-suggests that although Oct4 is necessary for the mainte-
gal94 plasmid (Dressel et al., 1999). The UAS tk-linked CAT reporternance of pluripotency, as demonstrated previously
vector was generated as previously described (Cooney et al., 1993).
(Nichols et al., 1998), it is not sufficient. Additional fac- Cell transfections in CV-1 cells with these plasmid constructions
tors that are repressed normally after gastrulation in were performed as previously reported (Cooney et al., 1998). The
GCNF-deficient embryos are most likely required to pCMV4-GCNF and pCMV4-GCNF-VP16 expression vectors were
constructed as previously described (Cooney et al., 1998, Hummelkespecify pluripotency, allowing some differentiation and
et al., 1998). The wild-type luciferase-based reporter constructsomitogenesis to occur, which eventually goes awry
(named 1) depicted in Figure 5B has been previously describedafter E8.5 due to the dual effect of loss of GCNF and
(Sylvester and Scho¨ler, 1994). Mutations of the proximal promoter
maintenance of Oct4 in the embryo. to create the vectors named 2 and 3 were introduced by PCR oligo-
On the basis of embryological and biochemical data, nucleotide-directed mutagenesis. In 2, the R2 direct repeat was
this report demonstrates that the orphan nuclear recep- changed to AACTCA; in 3, the R3 direct repeat was changed to
AACCTA (mutations in small letters). To create the vectors withouttor GCNF, is an important developmental gene that con-
the proximal enhancer (named 4, 5, and 6), the respective constructstrols Oct4 expression in the pluripotent embryonic and
1, 2, and 3 were shortened by digestion at the BamHI (1222) andembryonal cells. In particular, GCNF is necessary for
PstI (413) sites. P19 EC cells, plated at a density of 6
 105 cells/100
Oct4 gene repression in somatic cells and confinement mm dish, were transfected with the different expression plasmids
of the germline during early mouse embryogenesis. in the presence or absence of the reporter constructs, using the
FuGENE reagent according to the manufacturer’s instructions
Experimental Procedures (Roche). Cells were harvested 48 hr thereafter and proteins ex-
tracted for determination of luciferase activities. All luciferase activi-
Cell Culture, Protein Extraction, Protein Purification, ties were normalized to the coreporter activity of the pRL-TK Renilla
and Electrophoresis Mobility Shift Assays (EMSAs) luciferase control vector (Promega) using 100 ng of each extract.
P19 EC, F9 EC, RAC65 EC, 3T3, and 293 cells, seeded at a density High-level transfections were determined by transfecting the re-
of 1.5–5 
 105 cells/100 mm dish, were essentially cultured as pre- porter pCMV4-Gal and subsequent -galactosidase staining of one
viously described (Fuhrmann et al., 1999) in the presence or absence plate of the cells with the substrate X-Gal.
of 1M all-trans RA for the indicated time periods. Protein extraction
was performed as described (Fuhrmann et al., 1999). Production of
Two-Hybrid Assays and GST-Pulldown Assays
in vitro translated GCNF as well as GCNF antibody production and
The Lex DBD-GCNF fusion vector was constructed by insertion of
purification were performed as previously described (Hummelke et
the pABgal-GCNF fragment corresponding to the receptor C termi-
al., 1998). EMSAs were performed as described (Fuhrmann et al.,
nus into the EcoRI site of pEG202 (Dressel et al., 1999). The B42
1999) in the presence of different double-stranded oligonucleotide
AD-SMRT (F.L. or I.D.) and the B42 AD-NCoR (I.D.) fusion vectors
probes (with the sequences shown in Figure 1B). For supershift
were previously described (Dressel et al., 1999). The yeast two-
experiments, 1 l of specific antibody was added to the binding
hybrid assay was performed according to the manufacturer’s in-
reaction.
structions (Invitrogen) and assayed for -galactosidase activity.
The Gal4 DBD-GCNF fusion vector was constructed by insertion
Northern Blot Analysis and Reverse Transcription- of the cDNA fragment containing the GCNF LBD and hinge region
Polymerase Chain Reaction (RT/PCR) Analysis into the pM plasmid (Clontech); the VP16 AD-SMRT and VP16 AD-
Northern blot analysis was performed as previously described (Fuhr- NCoR fusion vectors were constructed by insertion of SMRT (F.L.),
mann et al., 1999). RT-PCR analysis was essentially carried out SMRT (I.D.), and N-CoR (I.D.) cDNA fragments into the pVP16 plas-
as described (Nichols et al., 1998), except that amplification was mid (Clontech), respectively. The mammalian two-hybrid assay was
achieved after 30 cycles of 94C, 1 min; 55C, 1 min; 72C, 1 min. performed according to the manufacturer’s instructions (Clontech)
Primer sets were as follows: GCNF 5-CTGAACAACGAACCTGTCTC- and assayed for luciferase activity.
3/5-TTGCTCTCTGAAGCCCTGTT-3, product 400 bp; SF-1 5-AAGG Full-length N-CoR and SMRT were expressed in the presence of
G CTTCTTCAAG CG CAC-3 /5 - AG GATAGAGGTAGCCAG 35S-methionine in rabbit reticulocyte lysate using the TNT kit (Pro-
CCA-3, product 459 bp; Oct4 5-GGCGTTCTCTTTGGAAAGGTG mega). GST-tagged GCNF was prepared and the GST pull-down
TTC-3/5-CTCGAACCACATCCTTCTCT-3, product 312 bp; -actin assay performed as previously described (Dressel et al., 1999).
(control) 5-GGCCCAGAGCAAGAGAGGTATCC-3/5-ACGCACGAT
TTCCCTCTCAGC-3, product 460 bp.
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